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B
uprenorphine was approved by the U.S. Food and Drug Administration
(FDA) in October 2002 as a Schedule III narcotic for use in treating 
opioid-dependent men and opioid-dependent women who are not pregnant. The
new medication’s unique pharmacological characteristics provide for less respi-
ratory depression or overdose risk than opioids such as morphine, heroin, methadone,
and oxycodone, as well as milder manifestations of withdrawal upon cessation.
This wide safety margin makes buprenorphine suitable for use in new treatment
settings, such as office practices, as well as more traditional opioid treatment pro-
grams. Further supporting this versatility, buprenorphine can be effective when
taken every other day or less frequently, and it is supplied in a combined formu-
lation with naloxone that is designed to reduce its potential for abuse. The med-
ication is therefore a welcome addition to a restricted treatment armamentarium,
especially now that LAAM (levo-alpha-acetylmethadol hydrochloride), another
widely used medication, is being discontinued by the manufacturer because of
safety concerns (U.S. Food and Drug Administration, 2003). This article reviews
buprenorphine’s pharmacology and clinical use, including appropriate dosing;
patient selection, education, and monitoring; and physician and staff training;
and it identifies important questions for research.
Buprenorphine is a new and attractive medication option for many opioid-addicted adults
and their physicians. Before initiating buprenorphine treatment, providers must be aware of
such critical factors as how the medication works, its efficacy and safety profile, how it is
used in opioid withdrawal as well as maintenance treatment, and how patients can best be
selected, educated about buprenorphine, and monitored throughout treatment. This article
reviews these important issues as well as requirements for physician and staff training and
needs for additional research on this unique medication.
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While buprenorphine’s manner of interacting
with the mu receptor gives rise to its most important
attributes and advantages in addiction treatment, the
medication also has a significant action at a second
receptor:
• Buprenorphine is an antagonist (i.e., prevents stim-
ulation) of the kappa opioid receptor (Cowan, Lewis,
and Macfarlane, 1977). Stimulation of the kappa
opioid receptor plays a role in producing some of
the major symptoms associated with opioid with-
drawal, such as chronic depression. By attaching to
the kappa receptor and slowing its activity, buprenor-
phine may induce positive mood and feelings of well-
being (Rothman et al., 2000).
There are two formulations of buprenorphine
for treating opioid dependence, a buprenorphine
hydrochloride (HCl) tablet (Subutex) and a combi-
nation tablet (Suboxone) containing buprenorphine
HCl plus naloxone HCl in a ratio of 4:1 (Fudala et al.,
1998; Mendelson and Jones, 2003; Mendelson et al.,
1996, 1997b, 1999; Preston, Bigelow, and Liebson,
1988). Both tablets produce similar clinical effects
when administered sublingually (Stoller et al., 2001).
Suboxone was developed because buprenorphine 
alone has potential for abuse (e.g., Pickworth et al.,
1993; Strain et al., 1997) and has been abused in other
countries (O’Connor et al., 1988; Singh et al., 1992;
Varescon et al., 2002). Unlike buprenorphine, 
naloxone is poorly absorbed and has little effect when
taken sublingually (Chiang and Hawks, 2003; Preston,
Bigelow, and Liebson, 1990); however, when injected
by an opioid-addicted person, naloxone can precipi-
tate an opioid withdrawal syndrome—a strong 
deterrent to diversion of Suboxone and its abuse by
injection (O’Brien et al., 1978). 
Research on Safety and Efficacy
Initial research showed that buprenorphine produced
signs and symptoms similar to those of morphine use
(for example, constricted pupils, sleepiness, and itchy
skin), yet, unlike morphine, it produced little physi-
cal dependence or respiratory depression and only
mild withdrawal symptoms, even when withdrawn
abruptly (Fudala et al., 1990; Jasinski, Pevnick, and
Griffith, 1978). In early efficacy studies, chronic
buprenorphine-treated subjects did not self-
administer heroin to the same extent as placebo-treated
subjects (Mello and Mendelson, 1980; Mello, Mendelson,
and Kuehnle, 1982). Given its positive psychoactive
PHARMACOLOGY AND CLINICAL TRIALS
Buprenorphine’s Effects
Buprenorphine is chemically an opioid. Like other
opioids, it produces most of its important effects by
interacting with a structure on nerve cells called the
mu opioid receptor (see “Heroin, Buprenorphine, and
Naloxone Effects at the Mu Opioid Receptor”). The
special characteristics that distinguish buprenorphine
from other opioids and make it useful for helping peo-
ple overcome opioid addiction result from the unique
ways it interacts with this receptor (e.g., Bickel and
Amass, 1995; Jasinski, Pevnick, and Griffith, 1978;
Martin et al., 1976):
• Buprenorphine is a partial agonist at (i.e., stimu-
lator of) the mu receptor. When the mu receptor
is stimulated, it sets in motion a chain of nerve cell
activities that underlies most of the familiar opioid
effects, for example, pain reduction, feelings of well-
being or pleasure, and respiratory suppression. By
stimulating the receptor only partially, buprenor-
phine yields those same effects, but with less inten-
sity than heroin, morphine, or methadone, all of
which stimulate the receptor fully (Johnson and
Strain, 1999). Whereas those drugs can cause pow-
erful euphoria, motivating continued abuse, buprenor-
phine provides a positive but moderate psychoac-
tive effect that reduces craving and helps patients
comply with their medication regimens (Jasinski,
Pevnick, and Griffith, 1978; Walsh et al., 1994).
• Buprenorphine has high affinity for the mu recep-
tor.That is, buprenorphine binds tightly to mu
receptors, more so than abused opioids and methadone
do. Consequently, if a patient takes an abused
opioid on top of buprenorphine, the medication
will block it from reaching the receptors and pro-
ducing the desired strong effects. Moreover, if
buprenorphine is given to an individual who has
already taken another opioid, it displaces the other
opioid from the receptors. This effect necessitates
care when a clinician initiates buprenorphine ther-
apy; depending on the dosage of buprenorphine,
the patient’s level of physical dependence, and when
he or she last administered an abused opioid, the
abrupt stripping of the other opioid from the mu
receptor can precipitate withdrawal.
• Buprenorphine disassociates (detaches) from the
mu opioid receptor slowly.This characteristic prob-
ably accounts for buprenorphine’s long duration
of action in the treatment of opioid dependence.
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effects, buprenorphine seemed likely to be accepted
by patients (Mello and Mendelson, 1995), while its
improved safety profile (Jasinski and Preston, 1995)
would provide treatment practitioners with a unique
medication for treating opioid dependence. 
Subsequently, numerous studies examined the
safety and efficacy of buprenorphine maintenance
treatment (Ahmadi, 2002; Amass, Kamien, and Mikulich,
2000; Fischer et al., 1999; Fudala and Johnson, 1995;
Fudala et al., 2003; Johnson, Jaffe, and Fudala, 1992;
Johnson et al., 1995a, 1995b, 2000; Kosten et al.,
1993; Ling et al., 1996; Mattick et al., 2003; Pani et
al., 2000; Perez de los Cobos et al., 2000; Petitjean 
et al., 2001; Schottenfeld et al., 1997, 2000; Strain et
al., 1994; Uehlinger et al., 1998). The only study to
compare buprenorphine, LAAM, and high-dose
methadone found that all three produced similar reduc-
tions in illicit opioid use and were superior to low-
dose methadone (Johnson et al., 2000).  
Many of the randomized controlled clinical
trials conducted with buprenorphine have limitations. 
Most of the trials were conducted with men only, in
Heroin, buprenorphine, and naloxone (represented above by blue polygons) produce contrasting effects because they interact differ-
ently with the brain’s mu opioid receptors (red pentagons).
First, the chemicals differ in how much each stimulates the receptors (represented above by the percentage of receptor “activity
zone” each fills). The stronger the stimulation, the more pronounced will be the opioid effects of pain relief, feelings of well-being,
respiratory depression, and so on. Heroin, classified as a full receptor agonist (stimulator), nearly fills the activity zone. Bupre-
norphine, a partial receptor agonist, fills a smaller portion of it. Naloxone does not stimulate the receptor at all.
Second, each chemical binds to the receptors more or less strongly (represented above by the percentage of receptor “affinity
zone” it fills). A chemical that forms a tighter bond can push one with a weaker bond off the receptors and take its place. Thus,
buprenorphine can push heroin off the receptors, and in doing so replace heroin’s full receptor stimulation with its own partial stim-
ulation. Buprenorphine also binds more tightly than naloxone.
Naloxone can compete with heroin for the receptors. Because naloxone can block heroin and other opioids from stimulating the
receptors while not itself stimulating them, it can precipitate opioid withdrawal and is classified as an opioid receptor “antagonist.”
Heroin, Buprenorphine, and Naloxone Effects at the Mu Opioid Receptor
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monitored outpatient settings as opposed to office set-
tings, over periods of less than a year, and with fixed
doses (whereas flexible doses would be expected to
produce better outcomes). Most studies used the
liquid form of buprenorphine, so a dose conversion
from liquid to tablet is necessary for proper inter-
pretation of the results. In addition, most studies with
tablets used Subutex, whereas Suboxone is the intended
first-line form of buprenorphine.  
Some studies have reported similar patient reten-
tion rates for buprenorphine and methadone (Johnson,
Jaffe, and Fudala,1992; Johnson et al., 2000; Pani 
et al., 2000; Strain et al., 1994). Where differences in
retention were observed, buprenorphine treatment
was associated with greater dropout rates. Although
the reason for this difference is not known, it is pos-
sible that:
• The buprenorphine induction was too slow (Fischer
et al., 1999; Mattick et al., 2003; Petitjean et al.,
2001);
• The maximum buprenorphine dose was too low
(Fischer et al., 1999; Kosten et al., 1993; Ling et al.,
1996; Mattick et al., 2003; Petitjean et al., 2001;
Schottenfeld et al., 1997); or
• Patients were able to terminate buprenoprhine treat-
ment more comfortably than methadone treatment
because of buprenorphine’s milder withdrawal effects
(Mattick et al., 2003). 
Despite its limitations, this research, in sum,
demonstrates that buprenorphine has efficacy similar
to methadone over a broad dose range. Trials that used
larger maintenance doses of the medications produced
greater decreases in illicit opioid use, a dose-response
relationship that confirms the medication’s causal con-
tributions to the desired outcome. (See “The Response
to Buprenorphine Is Dose Related and Comparable
to Methadone.”) There is a great deal of variation in
individuals’ responses to medication; consequently,
patients should receive dosage tailored to their indi-
vidual responses.
Though buprenorphine and methadone have
shown similar efficacy in controlled trials, the com-
parative mildness of buprenorphine’s positive psy-
choactive effects has raised questions about its effec-
tiveness for highly dependent patients (Walsh et al.,
1994). Although there are reports of effective treat-
ment of highly dependent patients with Subutex doses
higher than 32 mg (personal communication, Rolley
E. Johnson, Reckitt Benckiser Pharmaceuticals, Inc.,
September 6, 2003), buprenorphine’s limitations in
this population of patients warrant further study. 
Just as with methadone (Ernst et al., 2002), a
number of overdose deaths have been reported with
intravenous use or very high doses of the combina-
tion of buprenorphine and benzodiazepines (Kintz,
2002; Reynaud et al., 1998; Singh et al., 1992).
The interaction mechanism is unclear, but it appears
not to be related to the drugs’ absorption, distribu-
tion, metabolism, or elimination from the body
(Kilicarslan and Sellers, 2000). The interaction poten-
tial of sublingual buprenorphine and oral benzodi-
azepines is unclear. In controlled clinical trials in the
United States, one death has been reported of a patient
using oral benzodiazepine in conjunction with
buprenorphine.
Suboxone, the buprenorphine-naloxone com-
bination, has been shown to effectively treat opioid
dependence or block the effects of illicit opioids with-
out noticeable negative effects of naloxone (Amass,
Kamien, and Mikulich, 2000, 2001; Comer and
Collins, 2002; Harris et al., 2000; Strain et al., 2000,
2002). Given buprenorphine’s (particularly Suboxone’s)
lower potential for abuse and strong safety profile—
its plateau of subjective effects with increasing doses
and the fact that it causes little respiratory depres-
sion—it is considered a first-line medication option
for beginning opioid-dependence treatment (Fudala
et al., 2003; Ling and Compton, 1997).
THERAPEUTIC GOALS
Federal Requirements
As a medication that private physicians can prescribe
under the Drug Addiction Treatment Act of 2000
(Public Law 106-310, referred to as “DATA 2000”),
buprenorphine provides an alternative for patients
who do not have access to methadone clinics or do
not meet criteria for treatment in an opioid treatment
program. For example, admission criteria for metha-
done treatment clinics often include opioid depend-
ence for 1 year or more (Leshner, 2003). Patients
are potential candidates for buprenorphine treatment
through physicians’ offices if they meet the American
Psychiatric Association’s current opioid dependence
criteria (American Psychiatric Association, 2000).
However, if buprenorphine treatment is given in an
opioid treatment program, such as a methadone clinic,
patients must meet the same Federal guideline crite-
ria for admission that apply to methadone therapy
Given
buprenor-
phine’s (par-
ticularly Sub-
oxone’s) low
potential for
abuse and
strong safety
profile, it is
considered a
first-line med-
ication option
for beginning
opioid-
dependence
treatment.
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Medication
Buprenorphine 
Methadone 
Buprenorphine
Number of 
Subjects
(M/F)
23/6
20/9
21/9
16/12
736 total; 
≈1/3 F
Subjects 
Completing 
Study %
35
55
47
64
40
51
52
61
Opioid-
Negative Urine
Samples %a
23
42
28
55
19
29
33
38
Reference
Schottenfeld et al.,
1997
Ling et al., 1998
The Response to Buprenorphine Is Dose Related and Comparable to Methadone
Days of 
Treatment
(all groups)
168 
112
Dose (mg/d) 
4 
12
20 
65
1
4
8
16
(U.S. Department of Health and Human Services,
2001).
Under DATA 2000, physicians can apply to the
Center for Substance Abuse Treatment, a component
of the Substance Abuse and Mental Health Services
Administration (SAMHSA), for a waiver of the
Controlled Substance Act that will enable them to
treat up to 30 patients (O’Connor, 2000). Physicians
may be eligible for the waiver if they meet at least one
of the following criteria (SAMHSA, 2003):
• Certification in addiction medicine through the
American Board of Medical Specialties, American
Society of Addiction Medicine, or American
Osteopathic Association;
• Completion of at least 8 hours of approved train-
ing in the treatment or management of patients
dependent on opioids;
• Other training or experience that demonstrates their
ability to treat and manage opioid-dependent patients.
Physicians also must certify that they can pro-
vide or refer patients to needed ancillary services, such
as behavioral counseling, mental health care, and case
management (Clark, 2001).
Treatment Objectives
The objectives of buprenorphine therapy are iden-
tical to those of treatment with methadone (Fudala
and Johnson, 1995): 
Studies showing a dose-response relationship
Studies showing efficacy comparable to methadone
Buprenorphine
+ naloxone
Methadone
Buprenorphine
Methadone
8:2
16:4
45
90
2-32 (avg. 10.9 week
6, 11.2 week 13)
20-150 (avg. 52.6
week 6, 57.3 week 13)
162 total
across both
medication
groups
139/61
142/63
34 total across
both medica-
tion groups
50
59
64
64 
36 
52 
≈51b
≈49b
Amass, Kamien,
and Mikulich,
2000
Mattick et al.,
2003
118
91
a For all patients enrolled in treatment, except, in the study by Amass and colleagues, for patients who completed treatment.
b Urine samples that were scheduled but not provided by patients were counted as positive.
Buprenorphine,
while effective
for eliminating
illicit opioid
use, is not a
cure for opioid
dependence:
No medication
has been found
to change the
behaviors asso-
ciated with
illicit drug use.
These four studies clearly illustrate two key conclusions that emerged from the large body of clinical studies on buprenorphine 
conducted to date. The medication’s effects are dose related and comparable to those of methadone. The dosages of buprenorphine
and methadone used in these four studies mostly were low relative to current guidelines for optimal dosing, which may account,
among other possible reasons, for the low rates of opioid-negative urine samples among patients in some of the study arms. 
                     1995a) or lesser drug use
(Schottenfeld, Pakes, and Kos-
ten, 1998) than did men or
methadone-maintained women
(Jones et al., 2001).
The clinician should con-
sider a number of factors prior
to starting a patient on buprenor-
phine. First: The patient may be
taking other medications that
might make buprenorphine a
more, or less, attractive option.
Buprenorphine’s interactions with
other medications tend to be sim-
ilar to methadone’s but with some
notable differences (see “Alcohol
and Medication Interactions With
Buprenorphine and Methadone”).
In general, buprenorphine appears
to have few significant drug inter-
actions. When interactions occur,
they appear to increase the effects
of buprenorphine by decreasing
its metabolism. Such interactions
can easily be mitigated by a
reduced buprenorphine dose.
Second: Some co-occurring
medical conditions can be contra-
indications for buprenorphine
use. These could include diffi-
cult breathing or lung problems,
kidney or gallbladder problems,
head injury, severe mental dis-
orders, adrenal or thyroid dys-
function, urination problems, or enlarged prostate.
Patients taking buprenorphine who have hepatitis or
impaired liver function should be routinely moni-
tored, especially when taking high doses, because the
medication’s potential to increase liver damage has
not been fully evaluated (Petry et al., 2000).
The FDA has not approved methadone or
buprenorphine for use during pregnancy. Bupre- 
norphine is in FDA’s category C, a mid-level risk cat-
egory within the range A (low risk)-B-C-D-X.
Methadone is in category B. Category C drugs have
shown adverse effects on fetuses in animal studies and
have not been adequately studied in humans. 
Thousands of women have continued metha-
done maintenance throughout pregnancy with no
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Costs of Buprenorphine
And Access to Care
Buprenorphine is expected to
increase the availability of  addiction
treatment for an estimated 166,000
illicit opioid users and 1.5 million
problem users of prescription opi-
oids (Substance Abuse and Mental
Health Services Administration,
2003). But because buprenorphine
can be dispensed in office settings
and is more expensive than metha-
done, some providers are concerned
that only highly motivated, more
affluent patients with access to
social supports will be able to 
receive it. 
In fact, however, buprenorphine
costs less than most newly FDA-
approved medications (about $10
per 16-mg dose) and has been esti-
mated to be cost-effective (Barnett et
al., 2001). That buprenorphine may
be attracting new patients into treat-
ment can also be viewed as a benefit.
A recent study comparing patients
treated with buprenorphine in a
physician’s office to others treated
with the new medication in an opioid
treatment program showed that the
former were different in several
respects: They had fewer years of opi-
oid use, less injection drug use, and
greater rates of current prescription
opioid use (Sullivan et al., 2003). 
• To prevent opioid withdrawal signs and symptoms,
• To provide a comfortable induction onto the med-
ication, and
• To then attenuate the motivations (such as craving)
to use illicit opioids.
By eliminating illicit drug use, patients depend-
ent on opioids can begin to focus on repairing fam-
ily and social relationships, finding positive social 
support networks, obtaining fulfilling employment,
and engaging in new forms of recreation and other
activities that contribute to healthy, balanced 
living.
Buprenorphine, while effective for eliminating
illicit opioid use, is not a cure for opioid dependence:
No medication has been found to change the behav-
iors associated with illicit drug use. Like all other med-
ications for drug dependence, buprenorphine will
more successfully promote and sustain abstinence
when prescribed as one component of a complete
treatment regimen that also includes behavioral inter-
ventions (Montoya et al., 2003; National Consensus
Development Panel on Effective Medical Treatment
of Opiate Addiction, 1998).
On a societal level, treatment that includes
buprenorphine has been shown to reduce the harm-
ful effects of opioid dependence by reducing drug use
severity, increasing social status, and impeding the
spread of HIV/AIDS and other infectious diseases
(Fhima et al., 2001; Kakko et al., 2003; Mattick et
al., 2003). It may also provide a net economic advan-
tage, with increased costs for the medication and
for physician and nursing services offset by reduc-
tions in dispensing, counseling, and administrative
costs as well as some of the costs patients must incur
to obtain treatment (Rosenheck and Kosten, 2001).
(See “Costs of Buprenorphine and Access to Care.”) 
MEDICATION MANAGEMENT
Patient Selection
To date, few studies have examined which type of
patient is best treated with buprenorphine rather than
methadone. One study comparing buprenorphine-
and methadone-maintained patients observed that,
unique to buprenorphine patients, those with his-
tories of sedative dependence stayed in treatment
longer and used less cocaine (Schottenfeld, Pakes, and
Kosten, 1998). Other research has reported differ-
ential responses to buprenorphine between men and
women, with women showing greater (Johnson et al.,
Some co-
occurring med-
ical conditions
can be contra-
indications for
buprenorphine
use.
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Medication
Alcohol
Amantidine
Benzodiazepines 
Carbamazepine
Desipramine
Disulfiram
Fluoxetine
Fluvoxamine
HAART (highly
active antiretrovi-
ral therapy)
Indinavir
Ketoconazole
Naltrexone
Nevirapine
Omeprazole
Methadone
Effect
Increased effect due to
decreased methadone
metabolism
No change in effect
Increased effect; poten-
tially fatal
Decreased effect
Higher desipramine serum
levels
No change in effect
No change in effect
Increased effect due to
decreased methadone
metabolism
Decreased effect
Increased effect due to
decreased methadone
metabolism
Higher ketoconazole doses
not tolerated
Increased effect due to
decreased methadone
metabolism
Decreased effect
Increased effect reduces
respiration in rats
References
White and Irvine, 1999 
Kosten et al., 1992;
Oliveto et al., 1995 
Ernst et al., 2002;
Kilicarslan and Sellers,
2000; Kintz, 2002;
Reynaud et al., 1998;
Singh et al., 1992; 
Eap et al., 2002; Paetzold
et al., 2000; Schlatter et
al., 1999
Kosten et al., 1992;
Maany et al., 1989;
Oliveto, 1995
George et al., 2000;
Kreek, 1981; Tong et al.,
1980
Iribarne et al., 1998;
Oliveto et al., 1995
Bertschy et al., 1996;
DeMaria and Serota,
1999; Iribarne et al., 1998 
Carrieri et al., 2000;
McCance-Katz et al.,
2002
Fornataro, 1999; Iribarne
et al., 1998
Ibrahim et al., 2000;
Kosten et al., 2002
Eissenberg et al., 1996;
Johnson, 2001; Kosten et
al., 1990
Heelon and Meade, 1999
de Castro et al., 1996;
Kilicarslan and Sellers,
2000 
Buprenorphine
Effect
Increased effect due to
decreased buprenorphine
metabolism; can be fatal
No change in effect
Increased effect can be fatal
No change in effect
No change in effect
No change in effect
No change in effect
Increased effect due to
decreased buprenorphine
metabolism
No change in effect
Increased effect due to
decreased buprenorphine
metabolism
Increased effect due to
decreased buprenorphine
metabolism
Risk of opioid withdrawal
Increased effect due to
decreased buprenorphine
metabolism
No change in effect
Use
No medical use
Treatment 
for Parkinson’s 
disease
Treatment for
anxiety, sleep 
difficulty
Anticonvulsant
Antidepressant
Alcohol abuse
treatment  
Antidepressant
Antidepressant
HIV treatment
HIV/AIDS  treat-
ment
Antifungal agent
Alcohol abuse
treatment
HIV treatment
Gastrointestinal
treatment
Alcohol and Medication Interactions With Buprenorphine and Methadone
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Medication
Partial opioid 
agonists
Ritonavir
Saquinavir
Zidovudine
Use
Treatment of
pain
HIV treatment
HIV treatment
HIV treatment
Buprenorphine
Effect
Risk of opioid withdrawal
Increased effect due to
decreased buprenorphine
metabolism
Increased effect due to
decreased buprenorphine
metabolism
Methadone
Effect
Risk of opioid withdrawal
Increased effect due to
decreased methadone
metabolism
Increased zidovudine 
toxicity
In combination with
lamivudine and abdavir,
increased methadone
metabolism and with-
drawal
No methadone dose
change required for
lamivudine-zidovudine
combination
References
Strain et al., 1993
Clarke et al., 2002;a Iribarne et
al., 1998; McCance-Katz et al.,
2003;b Stevens et al., 2003a
Iribarne et al., 1998
McCance-Katz et al., 1998
Pardo Lopez et al., 2003
Rainey et al., 2002
Alcohol and Medication Interactions With Buprenorphine and Methadone (continued)
a In combination lopinavir-ritonavir, Clarke et al. (2002) and Stevens et al. (2003) showed increased methadone metabolism but no withdrawal or need for dose 
adjustment.
b McCance-Katz and colleagues (2003) showed ritonavir alone had no significant effect on methadone metabolism, but the lopinavir-ritonavir combination pro-
duced withdrawal and required dose adjustments. 
apparent significant adverse fetal effects 
(Kaltenbach, Berghella, and Finnegan, 1998; Kandall
et al., 1999; Wang, 1999). FDA acknowledges that
the potential benefits of methadone during pregnancy
may outweigh possible hazards, and both SAMHSA
and NIDA endorse methadone treatment for opioid-
dependent women, regardless of pregnancy. However,
because experience with buprenorphine is more lim-
ited and further studies are pending, current guide-
lines exclude the use of buprenorphine during preg-
nancy. They also recommend that women who become
pregnant while receiving maintenance therapy with
buprenorphine switch to methadone. Women initi-
ating opioid agonist treatment therefore require appro-
priate information to help them make informed deci-
sions about each medication’s risks and benefits in
case of pregnancy, including what they might expe-
rience should they become pregnant and change med-
ications during pregnancy. (See Johnson, Jones, and
Fischer, 2003, for a review of buprenorphine and preg-
nancy.) 
Currently, buprenorphine is recommended for
use only by patients aged 16 and older because safety
and effectiveness data for younger adolescents are
lacking. However, the use of heroin by American ado-
lescents is at its highest level since the 1960s (U.S.
Department of Justice, 1999), and results of an 
ongoing study at five sites in NIDA’s National Drug
Abuse Treatment Clinical Trials Network (CTN) may
prove illuminating. The CTN study is comparing 
the effectiveness, for 14- to 21-year-olds, of Suboxone
solely for detoxification (7 to 14 days) versus Suboxone
detoxification plus maintenance therapy (3 months),
when each is supplemented by twice-weekly
psychosocial support for 3 months (Woody, 2003).
This study may confirm the reported finding of 
Marsch and colleagues (2003) that in a 28-day out-
patient setting under double-blind conditions,
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buprenorphine was superior to clonidine—an anti-
hypertensive medication often used to alleviate opi-
oid withdrawal symptoms—in retaining patients in
treatment and reducing their opioid use. 
Exploring patients’ expectations for buprenor-
phine treatment is important. New medications often
generate unrealistic hopes. Explaining to the patient
what buprenorphine can do (block illicit opioid effects,
decrease craving) and what it cannot do (prevent him
or her from ever using drugs again) may help enhance
treatment outcomes. Conversely, some patients may
expect buprenorphine treatment to fail. Unless addressed,
such an expectation can become self-fulfilling.
The decision to use buprenorphine is not irre-
versible. Should a patient have intolerable side effects
or fail to respond to buprenorphine—that is, con-
tinue illicit opioid use after dose adjustments and sta-
bilization on a maintenance dose—he or she can eas-
ily be switched to methadone.
Initiating Therapy
The initial goals of buprenorphine therapy are 
to quickly minimize opioid withdrawal signs and
symptoms, maximize patient comfort, and achieve
an appropriate maintenance dose. When an opioid-
dependent patient presents for treatment and buprenor-
phine is selected as the appropriate medication, the
clinician must make several decisions: 
• Which buprenorphine tablet (Suboxone or Subutex)
should be used for induction into therapy and for
maintenance? 
• When should the first buprenorphine dose be admin-
istered? 
• What are the optimal induction dose and schedule
to achieve stabilized maintenance? 
Tablet Selection
For a patient who is dependent on a short-acting opi-
oid like heroin, Suboxone will probably be appro-
priate for both induction and maintenance. Suboxone
is also likely to be preferred in cases where medica-
tion is dispensed to be taken away from the office
or clinic. Although some research suggests that patients
on long-acting opioid agonists such as OxyContin
(oxycodone) or methadone may experience less severe
withdrawal symptoms if initially given Subutex (Amass,
Kamien, and Mikulich, 2000, 2001), a recent report
documents safe induction of therapy with Suboxone
for more than 900 patients (Cunningham-Rathner
et al., 2003). The induction was accomplished over 
3 days with minimal withdrawal effects, similar to
the 3 to 4 days of mild withdrawal symptoms observed
with induction of buprenorphine alone (Fudala
and Johnson, 1995). 
When To Administer Buprenorphine
Both theory (Martin et al., 1976) and early clinical
experience (personal communication, Rolley E.
Johnson, Reckitt Benckiser Pharmaceuticals, Inc.,
September 6, 2003) support a recommendation that
clinicians initiate buprenorphine therapy only after
clear and objective signs of opioid withdrawal are
present. The reason is that, as discussed, buprenor-
phine will displace other opioids from the patient’s
mu opioid receptors. This effect may propel a patient
who is not already in withdrawal into withdrawal if
buprenorphine does not also provide enough mu opi-
oid receptor stimulation to compensate for what the
other opioid was providing. Because buprenor-
phine stimulates the receptor less strongly than other
opioids, it will more likely achieve this compensation
if the concentration of other opioids in the patient’s
system is low.
Waiting to initiate buprenorphine therapy until
the patient enters withdrawal from the other opioids
entails some mild discomfort for the patient, but it
provides a good indication that the concentration of
other opioids is probably low enough that buprenor-
phine can be administered safely. For some patients,
the period for transition to buprenorphine may be as
little as 4 to 6 hours if they have been using short-
acting opioids or as much as 24 to 96 hours for long-
acting opioids (Amass, Kamien, and Mikulich, 2000,
2001; Bouchez, Beauverie, and Touzeau, 1998; Johnson,
Strain, and Amass, 2003; Law et al., 1997; Levin et
al., 1997; Lintzeris, 2000; Lintzeris et al., 2001; Strain
et al., 1995; Walsh et al., 1995).
The recommendation to initiate buprenorphine
treatment after withdrawal commences applies to
patients on both long- and short-acting opioids. The
potential persistence in the system of long-acting opi-
oids such as MS Contin (morphine), oxycodone, and
methadone, however, together with variations in
patients’ rates of metabolism and in their sublin-
gual absorption of buprenorphine, necessitate an 
additional consideration in the timing of buprenor-
phine initiation. Particularly if a patient has been 
taking a high dose of a long-acting opioid, the
Explaining to
the patient
what bupre-
norphine can
do and what 
it cannot do
may help
enhance treat-
ment out-
comes.
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concentration remaining in his or her body at the start
of withdrawal may be higher than buprenorphine can
compensate for. If this is the case, the patient may
experience an intensification of withdrawal when the
medication replaces the other opioid on the mu
opioid receptors. An illustration of these effects is the
observation that patients maintained on lower doses
of methadone (for example, 20 to 40 mg) appear to
have a smoother transition when buprenorphine is
introduced 20 hours after the last methadone dose
than do patients maintained at higher doses (60 mg
or more) and given buprenorphine 40 hours after the
last methadone dose (Strain et al., 1992; Walsh et al.,
1995). 
One option for easing the transition from a long-
acting opioid to buprenorphine is to reduce the dose
to 30 mg methadone or its equivalent while provid-
ing ancillary support to prevent relapse to illicit
opioid use; such supports could include non-opioid
medications to alleviate withdrawal symptoms and
intensive counseling or case management (Jasinski et
al., 1984; Johnson and Strain, 1999; Johnson, Strain,
and Amass, 2003; Strain et al., 1992, 1995; Walsh et
al., 1995). For some patients, a dose reduction to
30 mg methadone may not be possible or may entail
significant risk of relapse. Thus, for patients on higher
methadone doses, increasing the time between the
last long-acting opioid dose and the initial buprenor-
phine dose, so that objective signs of withdrawal are
present and maximal tolerable withdrawal is achieved,
should help avoid a buprenorphine-precipitated with-
drawal (Bouchez, Beauveries, and Touzeau, 1998;
Lintzeris et al., 2003). For patients on more than 
60 mg methadone who are unable to decrease the dose,
transfer to buprenorphine in a closely monitored
inpatient setting is suggested (Lintzeris et al., 2001). 
Optimal Induction Dosing and Schedule 
The initial daily buprenorphine dose currently rec-
ommended is 4 to 8 mg, although higher doses have
been given. Clinicians generally start with 4 mg
Suboxone, and if withdrawal signs do not worsen,
give a second 4-mg dose in 2 to 4 hours. Some clini-
cians provide an additional dose (2 to 4 mg) for the
patient to take at home if withdrawal symptoms re-
emerge during the first 24 hours.
Practitioners should monitor for indications
of buprenorphine-precipitated withdrawal, includ-
ing sweating, anxiety, cravings, and gastrointestinal 
symptoms such as abdominal cramps, diarrhea, and/
or nausea. Such symptoms may appear within 
11/2 hours after buprenorphine dosing, peak within
11/2 to 3 hours, and diminish thereafter (Lintzeris
et al., 2001). This differs from withdrawal caused by
underdosing of buprenorphine, which can occur dur-
ing the latter part of a 24-hour dosing interval. 
Clinicians can achieve the maintenance dose of
buprenorphine by doubling the dose each day up to
a maximum of 24 to 32 mg (Ling et al., 1998; Ling
and Smith, 2002). If induction occurs too slowly,
patients might terminate their treatment (Mattick et
al., 2003; Petitjean et al., 2001). A number of stud-
ies have shown that a target dose of 16 mg can be
reached in 2 to 3 days (Johnson, Strain, and Amass,
2003) with minimal withdrawal effects (Johnson et
al., 1989; Kuhlman et al., 1998). To manage the
patient’s transition from Subutex to Suboxone ther-
apy, the clinician needs simply to replace the dose
of Subutex with Suboxone containing the same amount
of buprenorphine.
Buprenorphine blood concentrations stabilize
after approximately 7 days of consistent dosing (Chiang
and Hawks, 2003). If withdrawal symptoms subse-
quently emerge during any 24-hour dosing inter-
val, the dose is too low and should be increased.
Maintenance
The optimal maintenance dose of buprenorphine is
one that suppresses withdrawal signs and symptoms
and enables the patient to cease illicit opioid use. The
amount of medication needed to accomplish these
goals will vary from patient to patient, in part because
individuals differ with respect to sublingual absorp-
tion (Chiang and Hawks, 2003; Mendelson et al.,
1997a), metabolism, and response to the medication.
A dose of between 4 and 24 mg per day has been sug-
gested as likely to be efficacious for many patients.
Although doses of 32 mg and higher are being used
and have been reported in the literature, going beyond
32 mg may not always enhance the medication’s effi-
cacy (Strain et al., 2002).
Once a maintenance dose is achieved, it should
not routinely require adjustments, as patients main-
tained on buprenorphine have not clearly demon-
strated tolerance for the medication. However, much
research has investigated dosing schedules (Amass
et al., 1994, 1998; Amass, Kamien, and Mikulich,
2000, 2001; Bickel et al., 1999; Greenwald et al.,
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2002; Petry et al., 2000; Petry, Bickel, and Badger,
2001). In general, once a stable buprenorphine
dose is achieved, the medication can be administered
every other day or, in some cases, three times weekly
(such as Monday, Wednesday, and Friday) (Johnson
et al., 2000; Mattick et al., 2003), which can improve
medication compliance and patient satisfaction (Amass
et al., 1998; Amass, Kamien, and Mikulich, 2001).
Extending the dosing interval to once every 4 days
increases withdrawal symptoms (Amass, Kamien, and
Mikulich, 2001; Gross et al., 2001; Petry, Bickel, and
Badger, 2001). If alternate-day dosing is desired, the
dose must be increased to the equivalent daily dose;
for instance, if the daily dose is 12 mg, then the every-
other-day dose should be 24 mg (Amass et al., 1994,
1998; Amass, Kamien, and Mikulich, 2000). If thrice-
weekly dosing is used, the Monday and Wednesday
doses should be twice the daily maintenance dose,
and the Friday dose 50 percent greater than the
Wednesday dose (Johnson et al., 2000). Dosing less
often than daily will be advantageous in opioid treat-
ment programs where take-home doses are prohib-
ited by government regulations or program polcies. 
Medical Withdrawal
The safety and efficacy of buprenorphine have been
clearly demonstrated in the context of medically
assisted withdrawal from opioids, and it appears that
buprenorphine is associated with fewer opioid with-
drawal signs and symptoms than would be expected
with methadone or LAAM (Lintzeris et al., 2003).
This characteristic may help clinicians retain patients
during medically assisted withdrawal, but sustained
abstinence is not expected to be any greater with
buprenorphine than with methadone. 
As more patients are treated with buprenorphine,
physicians and managed care organizations will seek
standardized withdrawal protocols, but no one pro-
tocol is appropriate for all patients. Protocols should
be tailored to patient needs and the inpatient or out-
patient setting (Lintzeris et al., 2001). Several reviews
have examined buprenorphine-assisted medical with-
drawal (Gowing, Ali, and White, 2002; Rosen and
Kosten, 1995); a thorough review of this topic is
beyond the scope of this article.
Because DATA 2000 specifies that physicians
can treat only 30 patients at a time with buprenor-
phine, some may feel compelled to use buprenorphine
primarily for medical withdrawal in order to meet the
demand for treatment. Hopefully physicians will
obtain certification for buprenorphine use in suffi-
cient numbers to fully exploit the medication’s poten-
tial to reduce the current unmet demand for treat-
ment (Vastag, 2003). 
As always, withdrawal of illicit opioids is only a
first step in the complete treatment process. Patients
need a specific psychosocial treatment plan to help
them maintain drug abstinence after completion of
withdrawal. 
Patient Monitoring
It is important to monitor patients, using best prac-
tice guidelines, to ensure that they are responding
positively to buprenorphine and other aspects of treat-
ment. SAMHSA is preparing practice guidelines
for buprenorphine and anticipates publishing them
as a Treatment Improvement Protocol (TIP 40) later
in 2004. Urinalysis is an important tool for patient
monitoring and can help determine whether patients
are reducing their use of illicit opioids. 
If patients are continuing to use opioids, they
may need an increased buprenorphine dose. However,
if the dose appears adequate, environmental factors
should be examined for situations associated with
continued drug use (for example, when a partner is
using) and appropriate interventions employed.
Buprenorphine is not detected in onsite or spot-
testing urinalysis drug screens. If compliance with
the medication is a concern, more sophisticated tests
can be ordered to detect buprenorphine metabo-
lites in the urine or other biological material, but such
tests are expensive and require more time. Faster and
cheaper buprenorphine detection kits should become
available in the near future. 
EDUCATING PATIENTS AND CAREGIVERS
Patient Education 
Basic information about buprenorphine should be
conveyed at the outset and reinforced throughout the
course of treatment. Face-to-face conversations, sup-
plemented by written fact sheets, are helpful. Important
instructions for patients include:  
• Let Subutex or Suboxone tablets dissolve under your
tongue; they are much less effective if swallowed.  
• Take no more than two tablets at a time; other-
wise you may swallow them by mistake.
• Wetting the mouth before placing the tablets under
your tongue can help the tablets dissolve faster. 
        phine or using larger doses than those prescribed
in combination with benzodiazepines can cause 
death (Kintz, 2002; Reynaud et al., 1998; Singh et
al., 1992). 
Patients who have a history of liver disease need
to be informed about the need for routine monitor-
ing, as increased liver enzyme levels have been reported
during buprenorphine maintenance therapy (Lange
et al., 1990; Petry et al., 2000b). And finally, warn all
patients that injecting Subutex may cause liver dam-
age (Berson et al., 2001a, 2001b). 
Physician and Staff Training
In response to the requirements of DATA 2000, train-
ing curricula have been developed to educate physi-
cians about buprenorphine (including its pharma-
cology, treatment goals and duration, side effects, and
drug interactions), appropriate induction and main-
tenance dosing for patients entering treatment, address-
ing individual patient problems, and guidelines for
professional conduct in delivering opioid-agonist
treatment (Lintzeris et al., 2002; Strain, 2001).
Physicians can obtain the required training through
professional organizations, including the American
Society of Addiction Medicine, American Psychiatric
Association, American Academy of Addiction Psychiatry,
and American Osteopathic Association. 
Members of the physician’s office staff who are
not familiar with treatment of opioid-dependent
patients will need explicit training. A staff orienta-
tion program should include:
• A basic introduction to addiction medicine.
• A description of  buprenorphine’s unique pharma-
cology, the protocols for treatment induction and
maintenance, and potential side effects or adverse
reactions.
• Principles regarding appropriate interactions with
patients—basic respect, a positive, nonjudgmental
attitude, and maintenance of consistent interper-
sonal boundaries. Guidelines for staff and patient
conduct will minimize manipulation by patients
and adverse staff-patient interactions.
• Principles of patient confidentiality.
• Rules for the storing, distribution, and adminis-
tration of medication, including policies with respect
to lost prescriptions. Consistent and therapeutic
responses must be developed, because the staff may
discover that some patients are misusing or divert-
ing their medication.
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• Don’t smoke for 10 to 15 minutes before you take
your medication. Not smoking seems to help the
tablets dissolve faster. 
• Be sure to tell your doctor or other health care pro-
fessional about any discomfort you feel. He or she
may be able to give you medication that will help. 
• Before you have any medical or dental treatment
that involves anesthesia or pain-relieving medica-
tion, be sure to tell your physician or dentist that
you are taking buprenorphine. The medications
may interfere with one another.
• Do not drive a car or operate machinery until you
are sure you can do so safely. 
Preparing patients for the possibility of some
temporary discomfort during the transition process
and developing a trusting patient-doctor relationship
are extremely important. It is especially important to
encourage patients to tell their health care provider
about any effects they feel, because temporary side
effects can often be alleviated with over-the-counter
medications like Tylenol for headache or Benadryl for
sleep or anxiety.
Warn patients that if they continue to use illicit
opioids, they may have difficulty stabilizing on buprenor-
phine, and that if they take their buprenorphine dose
shortly after use of an illicit opioid, they may experi-
ence transient withdrawal symptoms. Because of
buprenorphine’s potential to block the effects of other
opioids, it is critical to advise patients to alert other
treatment providers (such as dentists and emer-
gency room personnel) that they are taking buprenor-
phine before undergoing any medical procedure or
receiving treatment for injury or illness that involves
the use of opioids to control pain (see SAMHSA’s Web
site at www.buprenorphine.samhsa.gov or the manu-
facturer for guidance). 
In addition, patients  should be cautioned against
using buprenorphine in combination with other cen-
tral nervous system depressants such as alcohol and
benzodiazepines. And they should be counseled that
the side effects of buprenorphine are similar to those
of other opioid agonists; the most common are headache,
withdrawal syndrome, nonspecific pain, nausea, and
constipation. These side effects are not unexpected,
are generally mild and manageable, and often resolve
within 3 weeks (Mello and Mendelson, 1995).
Patients need to be made aware that misuse of
buprenorphine can have serious results. Just as with
methadone (Ernst et al., 2002), injecting buprenor-
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• An overview of the typical psychosocial issues that
opioid-dependent patients face.
• Guidance in responding to requests for informa-
tion or obvious patient needs. Identifying and estab-
lishing linkages with community resources prior to
treating patients will maximize positive treatment
experiences for both staff members and patients
(Strain et al., 2001).
• Protocols to handle disclosure of suicide risk, child
abuse, communicable diseases, and domestic violence.
A number of Internet resources exist to help physi-
cians and their staffs address these issues (see “Web
of Support”). 
RESEARCH NEEDS
Much has been learned about buprenorphine through
the 25 years’ research that culminated in FDA’s approval
of the medication. As buprenorphine enters into wide-
spread use in established opioid treatment settings
and general medical practices, new research issues
come to the fore. Among them are:
• Buprenorphine’s efficacy in special populations,
such as incarcerated people and adolescents;
• Its safety during pregnancy—potential effects of
buprenorphine treatment on the developing fetus,
including possibly long-term consequences; 
• Clinical determination of which patients are best
treated with buprenorphine and which with other
opioid-dependence treatments; 
• Suboxone’s potential for abuse by means of inhal-
ing or smoking (since buprenorphine is bioavail-
able through intranasal administration) (Lindhardt
et al., 2001); 
• The transition from methadone or other long-
acting mu opioids (such as morphine and oxy-
codone) in outpatient settings, where any with-
drawal discomfort may make the patient especially
vulnerable to relapse; 
• The effects of buprenorphine on cognitive function,
psychomotor performance, and immune function;
and  
• The potential interactions of buprenorphine with
medications prescribed to treat other chronic ill-
nesses (for example, HIV, hepatitis, and depression)
and to manage pain. 
CONCLUSION
Buprenorphine is a safe and effective treatment for
opioid-dependent men and opioid-dependent women
who are not pregnant. Several unique features enhance
buprenorphine’s appropriateness for some patients
and treatment settings. First, its partial mu opioid-
agonist properties provide a wide safety margin, with
relatively slim chances for severe overdose effects.
Second, buprenorphine’s long duration of action allows
for flexible, patient-tailored dose administration 
multiple times daily, daily, or at longer intervals. Third,
when injected by an opioid-dependent person who is
not buprenorphine-maintained, the combination of
buprenorphine plus naloxone (Suboxone) precipitates
immediate and significant withdrawal syndrome, a
deterrent to abuse.
The availability of a safe, effective medication
that physicians can use to treat opioid-dependent
patients in an office practice is an important advance.
Now patients with the illness of opioid addiction can
be helped in private with a medical treatment option
similar to that for other chronic illnesses. Buprenorphine
tremendously expands opportunities for delivering
addiction treatment in settings and geographical areas
where established treatment programs are scarce or
nonexistent, and for matching treatment to individ-
ual patients’ needs in all settings. 
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Web of Support
Among the many useful Web sites to visit:
• www.hipaa.samhsa.gov for guidance on patient confidentiality
• www.suboxone.com for manufacturer’s information on buprenorphine
treatment for physicians, patients, and families
• www.samhsa.gov for Federal requirements and other information on
medication-assisted treatment.
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Arthur Van Zee: Dr. Jones’s paper is very informative.
I found much that was new to me even after 7 months’
experience with buprenorphine. I wish I had it when
we were starting out.
Martin Doot:The information in this article is con-
sistent with other reviews of buprenorphine therapy
I’ve seen. I wish it had more on the psychosocial aspects
of drug treatment, though. 
J. Thomas Payte: If I had only one source, this arti-
cle is the one I would want to have. When it is pub-
lished, I want all the physicians in our programs to
have it as background reading. I particularly liked the
explanations of how partial agonists work and how
they differ from full agonists and antagonists. 
Programs and strategies
Van Zee: We are looking to buprenorphine as a pos-
sible solution to a very difficult situation. Our clinic
is in the heart of Appalachia, in the southwestern cor-
ner of Virginia. Until about 3 years ago we had no
large-scale opioid addiction, but the OxyContin epi-
demic changed that. There are now tens of thousands
of new opioid addicts in our region. Methadone treat-
ment programs may be 2 hours away by car. Try to
imagine a 23-year-old single mother getting her daugh-
ter up at 4:30 every morning to drive to Tennessee
to get a methadone dose. Because of these difficulties,
prior to buprenorphine, I would just detox patients
and set them up with our local counseling team. Now,
I can offer them comprehensive treatment with an
effective medication.
We’ve had some wonderful success stories already—
people who started induction 7 months ago and who
have come very far, not just in terms of abstinence,
but also in terms of real personal growth. We’ve also
had many lapses. I think I’ve initiated 46 patients
on buprenorphine; 23 are still in the program, and
about 15 to 17 are doing well.
Doot: I work in a multispecialty, office-based group
practice affiliated with a large teaching hospital near
Chicago. We’re looking at buprenorphine as a means
to incorporate more flexibility into our abstinence-
based treatment model. We intend to offer it for 
maintenance as well as to improve outcomes with 
abstinence-based treatment.
Our group participated in the buprenorphine
clinical trials because our State agency wanted an 
abstinence-based perspective on the medication. Patients
chose buprenorphine or traditional abstinence-based
therapy. Our counselors found that after a while they
had a group of patients they were encouraging to
use 12-step facilitation and relapse prevention tech-
niques, who were well past detox but still using buprenor-
phine. What came out of this was a new model, in
which we meet patients where they are, accept some
of the goals they set for themselves, and then move
them along the continuum of change.
Our counselors are comfortable with this model.
I’ve had some say to me, ‘I really think this patient
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RESPONSE: INTEGRATING BUPRENORPHINE THERAPY INTO 
CLINICAL PRACTICE
We’re looking
at buprenor-
phine as a
means to 
incorporate
more flexibility
into our 
abstinence-
based treat-
ment model.
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